CytoDyn Inc.

  • Home
  • About CytoDyn
    • Overview
    • Our Mission
  • Our Science
  • Pipeline
  • Our Team
    • Leadership Team
    • Scientific Advisory Board
    • Board of Directors
    • Join our Team
  • Publications & Posters
  • Newsroom
    • Press Releases
  • Investors
    • Overview
    • Investor FAQs
    • Investor Update Calls
    • Annual Meeting of Stockholders
    • Warrant Exercise Inquiries
    • Restricted Stock Inquiries
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

CytoDyn Announces President Takes Medical Leave of Absence

May 24, 2023 5:05pm EDT

CytoDyn to Hold Webcast to Provide a Company Update

Apr 05, 2023 8:30am EDT

CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

Dec 23, 2022 8:00am EST

CytoDyn to Host R&D Update on Wednesday, December 7, 2022

Nov 22, 2022 8:30am EST

CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues

Oct 28, 2022 5:15pm EDT

CytoDyn Announces Appointment of Additional Directors with Industry Experience

Oct 20, 2022 8:30am EDT

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

Sep 19, 2022 8:30am EDT

CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

Jul 13, 2022 8:30am EDT

CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab

Jul 11, 2022 8:30am EDT

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

Jun 22, 2022 8:30am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    Next
    © 2025 CytoDyn Inc. All Rights Reserved.
    Privacy Policy Legal Notice & Disclaimer Forward-Looking Statement Disclosure Sitemap